These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 19535439)

  • 1. Molecular characterization of clinical isolates of human immunodeficiency virus resistant to the protease inhibitor darunavir.
    Sasková KG; Kozísek M; Rezácová P; Brynda J; Yashina T; Kagan RM; Konvalinka J
    J Virol; 2009 Sep; 83(17):8810-8. PubMed ID: 19535439
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TMC310911, a novel human immunodeficiency virus type 1 protease inhibitor, shows in vitro an improved resistance profile and higher genetic barrier to resistance compared with current protease inhibitors.
    Dierynck I; Van Marck H; Van Ginderen M; Jonckers TH; Nalam MN; Schiffer CA; Raoof A; Kraus G; Picchio G
    Antimicrob Agents Chemother; 2011 Dec; 55(12):5723-31. PubMed ID: 21896904
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resilience to resistance of HIV-1 protease inhibitors: profile of darunavir.
    Lefebvre E; Schiffer CA
    AIDS Rev; 2008; 10(3):131-42. PubMed ID: 18820715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thermodynamic and structural analysis of HIV protease resistance to darunavir - analysis of heavily mutated patient-derived HIV-1 proteases.
    Kožíšek M; Lepšík M; Grantz Šašková K; Brynda J; Konvalinka J; Rezáčová P
    FEBS J; 2014 Apr; 281(7):1834-47. PubMed ID: 24785545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Binding kinetics of darunavir to human immunodeficiency virus type 1 protease explain the potent antiviral activity and high genetic barrier.
    Dierynck I; De Wit M; Gustin E; Keuleers I; Vandersmissen J; Hallenberger S; Hertogs K
    J Virol; 2007 Dec; 81(24):13845-51. PubMed ID: 17928344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GRL-0519, a novel oxatricyclic ligand-containing nonpeptidic HIV-1 protease inhibitor (PI), potently suppresses replication of a wide spectrum of multi-PI-resistant HIV-1 variants in vitro.
    Amano M; Tojo Y; Salcedo-Gómez PM; Campbell JR; Das D; Aoki M; Xu CX; Rao KV; Ghosh AK; Mitsuya H
    Antimicrob Agents Chemother; 2013 May; 57(5):2036-46. PubMed ID: 23403426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of gag mutations on selection of darunavir resistance mutations in HIV-1 protease.
    Lambert-Niclot S; Flandre P; Malet I; Canestri A; Soulié C; Tubiana R; Brunet C; Wirden M; Katlama C; Calvez V; Marcelin AG
    J Antimicrob Chemother; 2008 Nov; 62(5):905-8. PubMed ID: 18765410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced stability of monomer fold correlates with extreme drug resistance of HIV-1 protease.
    Louis JM; Tözsér J; Roche J; Matúz K; Aniana A; Sayer JM
    Biochemistry; 2013 Oct; 52(43):7678-88. PubMed ID: 24079831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GS-8374, a prototype phosphonate-containing inhibitor of HIV-1 protease, effectively inhibits protease mutants with amino acid insertions.
    Grantz Šašková K; Kozíšek M; Stray K; de Jong D; Rezáová P; Brynda J; van Maarseveen NM; Nijhuis M; Cihlár T; Konvalinka J
    J Virol; 2014 Mar; 88(6):3586-90. PubMed ID: 24371077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GRL-079, a Novel HIV-1 Protease Inhibitor, Is Extremely Potent against Multidrug-Resistant HIV-1 Variants and Has a High Genetic Barrier against the Emergence of Resistant Variants.
    Delino NS; Aoki M; Hayashi H; Hattori SI; Chang SB; Takamatsu Y; Martyr CD; Das D; Ghosh AK; Mitsuya H
    Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29463535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of clade-specific sequence polymorphisms on HIV-1 protease activity and inhibitor resistance pathways.
    Bandaranayake RM; Kolli M; King NM; Nalivaika EA; Heroux A; Kakizawa J; Sugiura W; Schiffer CA
    J Virol; 2010 Oct; 84(19):9995-10003. PubMed ID: 20660190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of flap mutations on structure of HIV-1 protease and inhibition by saquinavir and darunavir.
    Liu F; Kovalevsky AY; Tie Y; Ghosh AK; Harrison RW; Weber IT
    J Mol Biol; 2008 Aug; 381(1):102-15. PubMed ID: 18597780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resistant minority species are rarely observed in patients on darunavir/ritonavir monotherapy.
    Lambert-Niclot S; Flandre P; Valantin MA; Peytavin G; Sayon S; Morand-Joubert L; Delaugerre C; Algarte-Genin M; Katlama C; Calvez V; Marcelin AG
    J Antimicrob Chemother; 2012 Jun; 67(6):1470-4. PubMed ID: 22396434
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Four Amino Acid Changes in HIV-2 Protease Confer Class-Wide Sensitivity to Protease Inhibitors.
    Raugi DN; Smith RA; Gottlieb GS;
    J Virol; 2016 Jan; 90(2):1062-9. PubMed ID: 26559830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV-1 protease-substrate coevolution in nelfinavir resistance.
    Kolli M; Ozen A; Kurt-Yilmaz N; Schiffer CA
    J Virol; 2014 Jul; 88(13):7145-54. PubMed ID: 24719428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel Central Nervous System (CNS)-Targeting Protease Inhibitors for Drug-Resistant HIV Infection and HIV-Associated CNS Complications.
    Amano M; Salcedo-Gómez PM; Yedidi RS; Zhao R; Hayashi H; Hasegawa K; Nakamura T; Martyr CD; Ghosh AK; Mitsuya H
    Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31061155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV-1 protease inhibitor mutations affect the development of HIV-1 resistance to the maturation inhibitor bevirimat.
    Fun A; van Maarseveen NM; Pokorná J; Maas RE; Schipper PJ; Konvalinka J; Nijhuis M
    Retrovirology; 2011 Aug; 8():70. PubMed ID: 21864346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Binding of Clinical Inhibitors to a Model Precursor of a Rationally Selected Multidrug Resistant HIV-1 Protease Is Significantly Weaker Than That to the Released Mature Enzyme.
    Park JH; Sayer JM; Aniana A; Yu X; Weber IT; Harrison RW; Louis JM
    Biochemistry; 2016 Apr; 55(16):2390-400. PubMed ID: 27039930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular basis for substrate recognition and drug resistance from 1.1 to 1.6 angstroms resolution crystal structures of HIV-1 protease mutants with substrate analogs.
    Tie Y; Boross PI; Wang YF; Gaddis L; Liu F; Chen X; Tozser J; Harrison RW; Weber IT
    FEBS J; 2005 Oct; 272(20):5265-77. PubMed ID: 16218957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unusual binding mode of an HIV-1 protease inhibitor explains its potency against multi-drug-resistant virus strains.
    Weber J; Mesters JR; Lepsík M; Prejdová J; Svec M; Sponarová J; Mlcochová P; Skalická K; Strísovský K; Uhlíková T; Soucek M; Machala L; Stanková M; Vondrásek J; Klimkait T; Kraeusslich HG; Hilgenfeld R; Konvalinka J
    J Mol Biol; 2002 Dec; 324(4):739-54. PubMed ID: 12460574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.